Un método de ensayo de fármacos descubre una combinación eficaz para tratar el cáncer de pulmón de células pequeñas infosalus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infosalus.com Daily Mail and Mail on Sunday newspapers.
Thrust on eco, waste management projects in Orthodox church budget
Updated:
Updated:
Budget of ₹841 crore for fiscal 2021-22
Share Article
Budget of ₹841 crore for fiscal 2021-22
The managing committee of the Malankara Orthodox Syrian Church on Thursday approved a budget of ₹841 crore under various schedules for the fiscal 2021-22.
The budget, presented by association secretary Biju Oommen at an online meeting presided over by Baselios Mar Thoma Paulose II, gives thrust to projects for ecological conservation, waste management, and financial assistance to church members.
The meeting also decided to inaugurate the year-long platinum jubilee of the canonisation of Mar Gregorious of Parumala and Mar Baselios Yeldho of Kothamanglam in November this year.
Drug Duo Targeting ATR Enzyme Shrinks SCLC Tumors medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
1
A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer
Merck is leading more than ten clinical trials across DNA Damage Response (DDR) pathways in various tumor types
Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide.
E-Mail
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer. The scientists targeted a vulnerability in how the cancer cells reproduce, increasing already high levels of replication stress ¬¬ a hallmark of out-of-control cell growth in many cancers that can damage DNA and force cancer cells to constantly work to repair themselves. In a small clinical trial, the drug duo shrank the tumors of SCLC patients. The team reported its findings April 12 in
Cancer Cell.
While many patients with small cell lung cancer initially respond to chemotherapy, they lack an effective follow-up treatment. These patients usually live a matter of weeks after their first treatment stops working and their disease returns. Scientists at NIH s National Cancer Institute (NCI) and National Center for Advancing Translational Sciences (NCATS) teamed up to find another opti